Movement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data

Market Focus06-05

On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.

On the news front, the company recently presented key Phase II clinical data for its core product Tinengotinib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The poster presentation disclosed efficacy and safety results of Tinengotinib monotherapy in Chinese advanced cholangiocarcinoma patients who had progressed on prior FGFR inhibitor treatment. As of the data cutoff date, 50 patients were enrolled, with a median follow-up of 12 months. Per blinded independent central review (BICR), the objective response rate (ORR) was 28.0%, with 14 patients achieving confirmed partial response. While the data demonstrated durable anti-tumor activity and a manageable safety profile, the market reaction suggests investors may have anticipated stronger results.

Additionally, the company recently completed an H-share placement of 3,836,000 shares at HK$40.83 per share, and was selected for inclusion in the HKEX Tech 100 Index effective June 15.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142379650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142379650","market":"us","top_or_hot":-1,"title":"Movement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data","media":"Market Focus","content":"<p><p>On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.</p><p>On the news front, the company recently presented key Phase II clinical data for its core product Tinengotinib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The poster presentation disclosed efficacy and safety results of Tinengotinib monotherapy in Chinese advanced cholangiocarcinoma patients who had progressed on prior FGFR inhibitor treatment. As of the data cutoff date, 50 patients were enrolled, with a median follow-up of 12 months. Per blinded independent central review (BICR), the objective response rate (ORR) was 28.0%, with 14 patients achieving confirmed partial response. While the data demonstrated durable anti-tumor activity and a manageable safety profile, the market reaction suggests investors may have anticipated stronger results.</p><p>Additionally, the company recently completed an H-share placement of 3,836,000 shares at HK$40.83 per share, and was selected for inclusion in the HKEX Tech 100 Index effective June 15.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PharmJet AnKang-B Falls 5.41% in Regular Trading, Stock Under Pressure After ASCO Presentation of Key Phase II Clinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 15:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.</p><p>On the news front, the company recently presented key Phase II clinical data for its core product Tinengotinib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The poster presentation disclosed efficacy and safety results of Tinengotinib monotherapy in Chinese advanced cholangiocarcinoma patients who had progressed on prior FGFR inhibitor treatment. As of the data cutoff date, 50 patients were enrolled, with a median follow-up of 12 months. Per blinded independent central review (BICR), the objective response rate (ORR) was 28.0%, with 14 patients achieving confirmed partial response. While the data demonstrated durable anti-tumor activity and a manageable safety profile, the market reaction suggests investors may have anticipated stronger results.</p><p>Additionally, the company recently completed an H-share placement of 3,836,000 shares at HK$40.83 per share, and was selected for inclusion in the HKEX Tech 100 Index effective June 15.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1142379650","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142379650","pubTimestamp":1780644135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.On the news front, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"动静提示|药捷安康-B常规交易跌5.41%ASCO公布关键II期临床数据后股票承压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"On June 5, PharmJet AnKang-B (Yaojie Ankang-B) declined 5.41% in regular trading, trading at HK$32.14 per share, with trading volume of approximately HK$73.33 million.On the news front, the company recently presented key Phase II clinical data for its core product Tinengotinib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The poster presentation disclosed efficacy and safety results of Tinengotinib monotherapy in Chinese advanced cholangiocarcinoma patients who had progressed on prior FGFR inhibitor treatment. As of the data cutoff date, 50 patients were enrolled, with a median follow-up of 12 months. Per blinded independent central review (BICR), the objective response rate (ORR) was 28.0%, with 14 patients achieving confirmed partial response. While the data demonstrated durable anti-tumor activity and a manageable safety profile, the market reaction suggests investors may have anticipated stronger results.Additionally, the company recently completed an H-share placement of 3,836,000 shares at HK$40.83 per share, and was selected for inclusion in the HKEX Tech 100 Index effective June 15.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142379650","isCrawlerRequest":true}